13 of 15 Top BMY Drugs' Revenues Were Up Year to Year In the Third Quarter, 2021 | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  8230 of 8458  at  10/27/2021 3:01:32 PM  by

tocentsworth

The following message was updated on 10/27/2021 4:39:43 PM.

13 of 15 Top BMY Drugs' Revenues Were Up Year to Year In the Third Quarter, 2021

Per BMY's News Release this am, its newest approved drugs like Reblozyl, Zeposia, Breyanzi, and Abecma are growing quite well in their early post-launch stages. Abraxane surprised me as being one of the two drugs that didn't grow its revenues, but an earlier post on this MB has said that it is encountering some manufacturing problems. Not bad. JMHO.
 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 3  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...